EnquBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EnquBio is a private, preclinical-stage CRO founded in 2020, operating from San Diego's biotech hub. The company offers a technology-enabled service model, providing integrated platforms for ultra-high-throughput screening, high-dimensional flow cytometry, and ultrasensitive multiplex detection to support clients from early discovery to translational research. As a service provider, its revenue is generated from client projects, placing it in the 'Revenue Generating' category, though its financials and specific clientele are not publicly disclosed. EnquBio's value proposition lies in its advanced technological infrastructure and multidisciplinary expertise aimed at derisking and accelerating the drug discovery pipelines of its biopharma partners.

Drug DeliveryBiologics

Technology Platform

Integrated drug discovery platforms featuring Ultra-High-Throughput Screening (uHTS), a proprietary HTS² platform combining screening with NGS analytics, High-Dimensional Flow Cytometry, and Ultrasensitive Multiplex Cytokine Detection (MSD S-PLEX).

Opportunities

The growing trend of biopharma outsourcing R&D, especially for complex, technology-driven discovery work, presents a significant opportunity.

EnquBio's niche in high-content screening, immunology, and biomarker discovery aligns with the industry's shift towards biologics and targeted therapies, positioning it to serve both large pharma and a vibrant biotech sector.

Risk Factors

EnquBio faces intense competition in the preclinical CRO market from large global players and niche specialists.

Its project-based revenue model creates client concentration and biotech funding cycle risks, and as a service provider, it lacks the high-margin IP ownership of a therapeutics company.

Competitive Landscape

EnquBio competes in the broad preclinical CRO market against giants like Charles River Laboratories and LabCorp's Covance, as well as numerous specialized boutiques. Its differentiation is based on a focused integration of advanced screening, sequencing, and immunology platforms, rather than scale, aiming to win business through technological sophistication and deep biological insight.

More companies in Digital Health & Biotech SaaS →More companies in United States →